Hospital
Mercy Medical Center
Mercy Medical Center was paid $26.38M by Medicaid between Jan 2018 and Dec 2024, across 155 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoMERCY MEDICAL CENTER
CEDAR RAPIDS, IA 52403
CEDAR RAPIDS, IA 52403
33aNPI1720029333assigned 06/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.38M
24GClaims610,619
24DCodes billed155
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#5 of 29
Median peer was paid$6.37M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CHARLES, TIMOTHY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,924 | $3.68M | |
| 2019 | 94,536 | $3.30M | |
| 2020 | 69,745 | $2.49M | |
| 2021 | 92,944 | $4.41M | |
| 2022 | 101,183 | $5.07M | |
| 2023 | 93,141 | $4.48M | |
| 2024incomplete | 50,146 | $2.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 67,703 | 62,504 | $8.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 41,653 | 37,720 | $7.75M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 8.9% | 6,892 | 6,661 | $2.35M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.3% | 16,257 | 14,776 | $1.66M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 5,226 | 4,503 | $1.57M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 14,579 | 6,142 | $784K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 1,808 | 1,649 | $642K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 12,002 | 10,650 | $410K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 5,918 | 5,553 | $402K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 2,522 | 2,430 | $316K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 6,186 | 5,403 | $314K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,473 | 5,897 | $228K |
143 more codes
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 4,510 | $174K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 337 | $110K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,259 | $89K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 144 | $88K |
| 87081 | <1% | 13,467 | $77K | |
| 80053 | Comprehensive metabolic panel | <1% | 76,306 | $75K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 1,420 | $71K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,834 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,135 | $57K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 421 | $56K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 264 | $54K |
| 87581 | <1% | 1,424 | $49K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 515 | $44K |
| 36415 | Collection of venous blood by venipuncture | <1% | 55,981 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,335 | $42K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 342 | $37K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 451 | $37K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 321 | $37K |
| 80061 | Lipid panel | <1% | 3,523 | $37K |
| 87631 | <1% | 283 | $33K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 105 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 929 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,410 | $25K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 167 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 430 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 75,537 | $20K |
| 86480 | <1% | 479 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 927 | $19K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 635 | $17K |
| 29581 | <1% | 252 | $17K | |
| G0378 | Hospital observation service, per hour | <1% | 897 | $14K |
| 62323 | <1% | 54 | $13K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 187 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 85 | $10K |
| 83655 | <1% | 879 | $10K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 329 | $6K |
| 97803 | <1% | 817 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 94 | $4K |
| 94060 | <1% | 27 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 189 | $4K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 65 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 683 | $4K |
| 86738 | <1% | 193 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 19 | $3K |
| 86780 | <1% | 235 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 374 | $3K |
| 85027 | <1% | 635 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,969 | $3K |
| 80069 | <1% | 388 | $2K | |
| 87340 | <1% | 216 | $2K | |
| 59025 | Fetal non-stress test | <1% | 16 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 18 | $2K |
| 87480 | <1% | 344 | $2K | |
| 87660 | <1% | 344 | $2K | |
| 87510 | <1% | 344 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $2K |
| 94726 | <1% | 30 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,996 | $2K |
| 80050 | General health panel | <1% | 32 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 17 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,513 | $1K |
| 97597 | <1% | 25 | $1K | |
| 87088 | <1% | 241 | $1K | |
| 84439 | <1% | 161 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $943.72 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 27 | $878.23 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 18 | $851.36 |
| 82570 | <1% | 156 | $671.80 | |
| 83721 | <1% | 125 | $654.85 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 394 | $629.57 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 9,547 | $549.02 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,324 | $377.87 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19 | $365.86 |
| 87486 | <1% | 19 | $365.86 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,456 | $355.64 |
| 82947 | <1% | 67 | $321.02 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,770 | $316.70 |
| 73610 | <1% | 41 | $306.84 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,208 | $303.93 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,356 | $258.80 |
| 83690 | <1% | 11,940 | $257.65 | |
| 85610 | <1% | 3,095 | $253.86 | |
| 81025 | <1% | 6,022 | $248.91 | |
| 81001 | <1% | 6,862 | $247.66 | |
| 72100 | <1% | 13 | $243.28 | |
| 84153 | <1% | 13 | $231.66 | |
| 73630 | <1% | 31 | $230.13 | |
| 84484 | <1% | 7,583 | $212.87 | |
| 85018 | <1% | 100 | $191.16 | |
| 83735 | <1% | 1,135 | $176.17 | |
| 84156 | <1% | 67 | $166.78 | |
| 83540 | <1% | 47 | $163.76 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 22 | $162.83 |
| 84466 | <1% | 28 | $159.96 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,415 | $158.75 |
| 84703 | <1% | 1,330 | $148.40 | |
| 82043 | <1% | 32 | $142.85 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 757 | $140.81 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,630 | $140.44 |
| 87186 | <1% | 34 | $134.09 | |
| 82607 | <1% | 14 | $131.58 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,806 | $121.05 |
| 82728 | <1% | 16 | $107.99 | |
| 84702 | <1% | 46 | $102.13 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 285 | $95.75 |
| 86140 | <1% | 427 | $75.30 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,739 | $69.09 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 17 | $42.32 |
| 81003 | <1% | 1,472 | $37.11 | |
| 85652 | <1% | 39 | $34.06 | |
| 82077 | <1% | 101 | $33.48 | |
| 85379 | <1% | 224 | $29.58 | |
| J3490 | Unclassified drugs | <1% | 1,181 | $29.25 |
| 85007 | <1% | 48 | $24.60 | |
| 73562 | <1% | 18 | $17.88 | |
| 94010 | <1% | 13 | $15.24 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,952 | $13.26 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 58 | $9.75 |
| 82977 | <1% | 46 | $8.21 | |
| 83880 | <1% | 268 | $7.17 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 925 | $6.35 |
| 85730 | <1% | 322 | $6.19 | |
| A9270 | Non-covered item or service | <1% | 42,873 | $4.54 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 194 | $4.48 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 825 | $1.75 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 337 | $0.53 |
| 94729 | 0% | 42 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 43 | $0.00 |
| 84145 | 0% | 32 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 31 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 331 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 316 | $0.00 |
| 87807 | 0% | 556 | $0.00 | |
| 99156 | 0% | 18 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 31 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 229 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 29 | $0.00 |
| 96376 | 0% | 49 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 37 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 64 | $0.00 |
| 82550 | 0% | 13 | $0.00 | |
| 83605 | 0% | 45 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHARLES, TIMOTHY (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Medical Center | Cedar Rapids, IA | $5.17M |
| Mercy Medical Center | Cedar Rapids, IA | $2.77M |
| Mercy Care Management, INC | Cedar Rapids, IA | $2.19M |
| Mercy Care Management, INC | Cedar Rapids, IA | $1.62M |
| Mercy Physician Associates, INC | Cedar Rapids, IA | $357K |
| Mercy Medical Center | Cedar Rapids, IA | $222K |
| Mercy Physician Associates, INC | Cedar Rapids, IA | $200K |
| Mercy Physican Associates INC | Cedar Rapids, IA | $170K |
| Mercy Surgery Center LLC | Hiawatha, IA | $68K |
| Mercy Physician Associates INC | Central City, IA | $48K |
| Mercy Physician Associates, INC | Cedar Rapids, IA | $27K |
| Mercy Care Management, INC | Hiawatha, IA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.